In this episode, we look at the unique policy challenges presented by cell and gene therapies from research & development through to patient access; and the role of multi-stakeholder collaborations, in particular those active in supporting European policymaking. How can we, together, deliver these innovative therapies to patients and society, efficiently and safely? 

Guests:

• Amanda Bok, Chief Executive, European Haemophilia Consortium (EHC)

• Alexander Natz, CEO, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

----

Abbreviations:

• ATMPs: Advanced therapy medicinal products

• EBMT: European Society for Blood and Marrow Transplantation

• GBA: Gemeinsamer Bundesausschuss 

• HTA: Health technology assessment

• MEPs: members of European Parliament